Repositorio Dspace

Long-term Effectiveness, Treatment Persistence, and Timing of Virological Failure With Long-Acting Cabotegravir Plus Rilpivirine in Real-World HIV Care: RELATIVITY Cohort

Mostrar el registro sencillo del ítem

dc.contributor.author Buzon, Luis
dc.contributor.author Cabello-Clotet, Noemi
dc.contributor.author Montes, María-Luisa
dc.contributor.author Galindo, María-José
dc.contributor.author Maria-Martínez, Rosa
dc.contributor.author Santacreu, Mireia
dc.contributor.author Remedios-Aleman, María
dc.contributor.author Torralba, Miguel
dc.contributor.author Fanjul, Francisco
dc.contributor.author Gutiérrez-Cuadra, Manuel
dc.contributor.author Rodríguez, Adrián
dc.contributor.author Crusells, María-José
dc.contributor.author Navarro, María
dc.contributor.author Aguilera-García, María
dc.contributor.author Hidalgo-Tenorio, Carmen
dc.contributor.author Morano, Luis-Enrique
dc.contributor.author Vinuesa, David
dc.contributor.author Bernal-Morell, Enrique
dc.contributor.author de-Andres, Carlos
dc.contributor.author Pernas, Hadrian
dc.contributor.author Tiraboschi, Juan
dc.contributor.author Bendala, Alejandro
dc.contributor.author Vivancos, María-Jesús
dc.contributor.author Diez, Cristina
dc.contributor.author Soria, Guillermo
dc.contributor.author Pérez, Desire
dc.contributor.author Cairo, Mireia
dc.contributor.author Romero, Alberto
dc.contributor.author Cabo, Rebeca
dc.contributor.author Soler, Josefa
dc.contributor.author Sepulveda, María-Antonia
dc.contributor.author Bravo-Urbieta, Joaquín
dc.contributor.author Escrich, Cristina
dc.contributor.author Ferreira, Eva
dc.contributor.author Valentin, Beatriz
dc.contributor.author Muelas, Magdalena
dc.contributor.author Lucas-Dato, Ana
dc.contributor.author Gómez, Albert
dc.contributor.author Cerezales, Ana
dc.contributor.author Losa, Juan-Emilio
dc.contributor.author Sanz, Jose
dc.contributor.author Masia, Mar
dc.contributor.author Corte-García, Juan-José
dc.contributor.author Antoli, Ana
dc.contributor.author Gainzarain, Juan-Carlos
dc.contributor.author Estebanez, Miriam
dc.contributor.author Barragan, Patricia
dc.contributor.author Clavero, Marta
dc.contributor.author Ferrero, Oscar
dc.date.accessioned 2026-11-11T09:05:34Z
dc.date.available 2026-11-11T09:05:34Z
dc.date.issued 2026-09-29
dc.identifier.citation Buzón L, Cabello-Clotet N, Montes ML, Galindo MJ, María Martínez R, Santacreu M, et al. Long-term Effectiveness, Treatment Persistence, and Timing of Virological Failure With Long-Acting Cabotegravir Plus Rilpivirine in Real-World HIV Care: RELATIVITY Cohort. Open Forum Infectious Diseases. 29 de septiembre de 2026;13(10):ofag622. doi:10.1093/ofid/ofag622
dc.identifier.issn 2328-8957
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29177
dc.description.abstract Background Long-acting injectable cabotegravir plus rilpivirine (CAB + RPV LA) is an established maintenance option for virologically suppressed people with human immunodeficiency virus-1 (HIV-1), but long-term real-world persistence and virological failure (VF) data remain limited. Methods RELATIVITY is an ongoing nationwide ambispective multicenter cohort of adults with HIV who switched from suppressive oral antiretroviral therapy to CAB + RPV LA in routine care in Spain. Data through 1 March 2026 were analyzed. The outcomes were virological suppression, treatment persistence, protocol-defined VF, and time to discontinuation-related events. Virological failure was defined as 2 consecutive HIV-1 RNA values ?200 copies/mL or 1 value ?500 copies/mL prompting discontinuation. Results Among 3349 participants, 3343 had valid follow-up dates; the median follow-up was 25.1 months (19.3-30.8). Virological suppression was documented in 3197/3349 (95.5%) overall and 3197/3309 (96.6%) with an evaluable closest viral load; 40 (1.2%) lacked an evaluable value. Injection adherence was ?90% in 3257/3280 (99.3%) evaluable participants. Overall, 2979/3349 (89.0%) remained on CAB + RPV LA. Virological failure occurred in 28/3349 (0.8%); 20/28 (71.4%) occurred within the first 12 months after switching. Emergent integrase strand transfer inhibitor and/or nonnucleoside reverse transcriptase inhibitor resistance was detected in 19/28 VF cases, and 24/28 achieved virological suppression after switching to oral therapy. Treatment-limiting injection-site reactions and systemic adverse events occurred in 2.4% and 1.6%, respectively. Conclusions Long-acting injectable cabotegravir plus rilpivirine showed high virological suppression and persistence beyond 2 years in routine care. Virological failure was uncommon and clustered mainly within 12 months, supporting early virological monitoring and prompt resistance-guided management.
dc.language.iso eng
dc.publisher OXFORD UNIV PRESS INC
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.title Long-term Effectiveness, Treatment Persistence, and Timing of Virological Failure With Long-Acting Cabotegravir Plus Rilpivirine in Real-World HIV Care: RELATIVITY Cohort
dc.type info:eu-repo/semantics/article
dc.relation.publisherversion https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofag622/8914524
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1093/ofid/ofag622
dc.journal.title Open Forum Infectious Diseases


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta